A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subjects.

Inclusion Criteria:Age ≥ 12 to < 18 years at Day 1.Body weight ≥ 40 kg at screening.History of inadequate response to TCS of medium or higher potency within 6 months (with or without TCI).EASI score ≥ 16.vIGA-AD score ≥ 3.≥10% body surface area (BSA) of AD involvement.Worst pruritus NRS ≥ 4.Exclusion Criteria:Treatment with a biological product within 12 weeks or 5 half-lives, whichever is longer, prior to Day 1.Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1:Systemic corticosteroidsSystemic immunosuppressantsPhototherapyOral or Topical Janus kinase inhibitorsTreatment with any of the following medications or therapies within 1 week, prior to Day 1:TCSTCITopical phosphodiesterase type 4 inhibitorsOther topical immunosuppressive agents